Acurx Pharmaceuticals Inc Ordinary Shares ACXP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update
-
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference
-
Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat
-
Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
-
Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026
-
Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
-
Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update
-
New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM EST - Show #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Vivos Therapeutics (NASDAQ:VVOS)
Trading Information
- Previous Close Price
- $1.46
- Day Range
- $1.44–1.52
- 52-Week Range
- $1.33–10.10
- Bid/Ask
- $1.50 / $1.51
- Shares Outstanding
- 4.30M
- Market Cap
- $6.45M
- Volume/Avg
- 89,729 / 114,279
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
- Website
- https://www.acurxpharma.com
Valuation
|
Metric
|
ACXP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.70 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ACXP
|
|---|---|
Quick Ratio | 3.68 |
Current Ratio | 3.78 |
Interest Coverage | — |
Quick Ratio
ACXP
Profitability
|
Metric
|
ACXP
|
|---|---|
Return on Assets (Normalized) | −88.24% |
Return on Equity (Normalized) | −138.85% |
Return on Invested Capital (Normalized) | −141.91% |
Return on Assets
ACXP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|JzM$?z | LOCK|YH%&C | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|x@G?pm | LOCK|@J>!F | $70B | |||
| argenx SE ADR
ARGX
| LOCK|xhcg#Sb | LOCK|lRK | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&?t$?? | LOCK|!DtJP | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<!D^?v | LOCK|><! | $36B | |||
| Moderna Inc
MRNA
| LOCK|y<z#%tH | LOCK|T# | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|p<>%$Nkl | LOCK|?Q^$k | $25B | |||
| Incyte Corp
INCY
| LOCK|#GS$S?^ | LOCK|j%G | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|lNF^hj | LOCK|!Sh | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|D?^$D& | LOCK|z>% | $17B |
United States